Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

epithelial and subepithelial corneal dystrophy - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

epithelial and subepithelial corneal dystrophy

MONDO:0000763

Also known as:epithelial and subepithelial dystrophy

Overview

OnsetCHILDHOOD, ADULT

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

Age of onset: childhood, adulthood.

GeneReviews

Clinical Guidance

Mucolipidosis IV (MLIV) is a neurodevelopmental disorder with a gradual, late-onset neurodegenerative component. The phenotype in affected individuals can be either typical/severe (~95% of individuals) or atypical/mild (~5% of individuals) . Although individuals with MLIV generally survive to adulthood, life expectancy is reduced compared to healthy individuals by either secondary complications of severe neurologic disability or kidney failure.

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

Mucolipidosis IV (MLIV) should be suspected in any individual with the following clinical and laboratory findings.

Clinical findings

Early onset of developmental delay whether static, as in cerebral palsy, or progressively declining with loss of previously acquired cognitive and motor abilities
Dystrophic retinopathy with or without corneal clouding

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for epithelial and subepithelial corneal dystrophy. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

No clinical practice guidelines for mucolipidosis IV (MLIV) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with MLIV, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with Mucolipidosis IV

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

Table 5. Recommended Surveillance for Individuals with Mucolipidosis IV

System/Concern

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for epithelial and subepithelial corneal dystrophy.

10 publications have been identified in PubMed for epithelial and subepithelial corneal dystrophy. Research spans Case Report / Case Series (60%), Epidemiology / Natural History (20%), and Review / Meta-Analysis (10%).

Research Type	Count	% of Total
Patient case studies	6	60%

Data assembled from 3 of 12 sources · Last updated Oct 4, 2026, 3:02 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

GeneReviews

Differential Diagnosis

The earliest signs of mucolipidosis IV (MLIV) include axial hypotonia, developmental delay, and strabismus, which are nonspecific and often lead to a provisional diagnosis of cerebral palsy. However, the finding of corneal clouding in combination with these neurologic features is relatively specific and should trigger further workup for MLIV. Eye Findings Table 2. Disorders with Eye Findings of Interest in the Differential Diagnosis of Mucolipidosis IV

Ophthalmologic Phenotype	Gene(s)	Disorder	MOI
ARSB	MPS VI (OMIM 253200)	AR GALNS	MPS IVA
GLB1	GM1 gangliosidosis MPS IVB (See GLB1-Related Disorders.)	AR	—
GNPTAB	ML II ML III/ (See GNPTAB-Related Disorders.)	AR	—
GNPTG	ML III	AR GNS HGSNAT NAGLU SGSH	MPS III

Source: GeneReviews — "Mucolipidosis IV"

System/Concern	Evaluation	Comment
Neurologic	Neurologic eval	To incl brain MRI; Consider EEG if seizures a concern.
Development	Developmental assessment	To incl motor, adaptive, cognitive, speech-language eval by neuropsychologist; Eval for early intervention / special education
Musculoskeletal	Orthopedics / physical medicine rehab / PT/OT eval	To incl assessment of:; Gross motor fine motor skills; Contractures; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
Eyes	Ophthalmologic eval	To assess for vision deficits, corneal clouding, strabismus, cataract, retinal changes Gastrointestinal/
Feeding	Gastroenterology / nutrition / feeding team eval	To incl eval of aspiration risk nutritional status; Consider eval for gastrostomy tube placement in those w/dysphagia /or aspiration risk.
Renal	Blood cystatin C level	By early adolescence Hematologic
counseling	By genetics professionals1	To obtain a pedigree inform affected persons their families re nature, MOI, implications of MLIV to facilitate medical personal decision making Family support/ resources
Treatment of Manifestations in Individuals with Mucolipidosis IV Manifestation/Concern	Treatment	Considerations/Other Developmental delay /
Intellectual disability	See .	—
Hypotonia	Ankle-foot orthotics in individuals w/hypotonia weakness of ankle dorsiflexion	PT rehab can help strengthen core muscles improve posture. Spasticity dystonia
Epilepsy	Standardized treatment w/ASM by experienced neurologist	Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.; Education of parents/caregivers1 Abnormal vision /or strabismus
Ocular irritation	Topical lubricating eye drops, artificial tears, gels, or ointments for management of intermittent ocular irritation seen frequently in younger children	Use preservative-free drops only.; Consult ophthalmologist before treatment. Poor weight gain / Failure to thrive
Gastrointestinal	Establish care w/gastroenterologist for management of constipation bile reflux (nonacidic in context of achlorhydria).	—
Kidney failure	Supportive care by nephrologist	—
Iron deficiency anemia	Iron supplementation as needed (e.g., oral ferrous sulfate)	Intravenous supplementation only in symptomatic persons ASM = anti-seizure medication; OT = occupational therapy; PT = physical therapy 1. Education of parents/caregivers regarding common seizure presentations is appropriate.

Kisho

epithelial and subepithelial corneal dystrophy

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Typical MLIV

Establishing the Diagnosis

Differential Diagnosis

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Recent Publications

epithelial and subepithelial corneal dystrophy

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Typical MLIV

Establishing the Diagnosis

Differential Diagnosis

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Recent Publications